The OHSU board of directors and Gov. Kotek announce their intent to appoint Steve Stadum interim president Friday, Nov. 1. The board unanimously approves the appointment at a public board meeting Nov. 4.

The OHSU board of directors and Gov. Kotek announce their intent to appoint Steve Stadum interim president Friday, Nov. 1. The board unanimously approves the appointment at a public board meeting Nov. 4.

The OHSU board of directors and Gov. Kotek announce their intent to appoint Steve Stadum interim president Friday, Nov. 1. The board unanimously approves the appointment at a public board meeting Nov. 4.

The OHSU board of directors and Gov. Kotek announce their intent to appoint Steve Stadum interim president Friday, Nov. 1. The board unanimously approves the appointment at a public board meeting Nov. 4.

Six young patients from OHSU Doernbecher share with their hometown newspapers their experience participating in the 20th annual Doernbecher Freestyle program, which has raised more than $40 million to support the children’s hospital’s vital mission.

The OHSU board of directors and Gov. Kotek announce their intent to appoint Steve Stadum interim president Friday, Nov. 1. The board unanimously approves the appointment at a public board meeting Nov. 4.

Pangea Biomed announced a pilot collaboration with the OHSU Knight Cancer Institute to explore the ability to predict personalized cancer treatment response using data processed through the Serial Measurements of Molecular and Architectural Responses to Therapy, or SMMART, Clinical Trials Program.

Flavio Rocha, M.D., is a candidate for the American Society for Clinical Oncology Nominating Committee, a leadership role with a three-year term.

OncoDaily features the 11 new Cancer Moonshot Scholar Awardees, including Haijiao Zhang, M.D., and Ramon Barajas, M.D.

A Medscape article on CAR-T therapy cites information on the OHSU Knight Cancer Institute website describing the treatment’s process of harnessing the power of a patient’s own T cells, which are then “genetically modified to make the chimeric antigen receptor, or CAR, [which] protein binds to specific proteins on the surface of cancer cells.”